A Case of Severe Pneumocystis Pneumonia in a Thyroid Cancer Patient Receiving Lenvatinib
International Journal of Thyroidology
; : 127-131, 2019.
Article
Dans En
| WPRIM
| ID: wpr-785838
Responsable en Bibliothèque :
WPRO
ABSTRACT
Lenvatinib is a multitargeted tyrosine kinase inhibitor approved for use in patients with iodine-131–refractory thyroid cancer. The common adverse events of lenvatinib include hypertension, proteinuria, fatigue, and diarrhea. To date, no report on Pneumocystis pneumonia (PCP) in patients receiving lenvatinib has been published. Here, we present a case of severe PCP that led to the death of a 79-year-old woman who was diagnosed with poorly differentiated thyroid cancer and received lenvatinib. The development of PCP should be considered when patients taking lenvatinib show clinical symptoms of pneumonia, and regular chest X-ray follow-up is needed for patients receiving lenvatinib.
Texte intégral:
1
Indice:
WPRIM
Sujet Principal:
Pneumocystis
/
Pneumopathie infectieuse
/
Pneumonie à Pneumocystis
/
Protéinurie
/
Thorax
/
Glande thyroide
/
Protein-tyrosine kinases
/
Tumeurs de la thyroïde
/
Études de suivi
/
Pneumopathies interstitielles
Type d'étude:
Observational_studies
/
Prognostic_studies
Limites du sujet:
Aged
/
Female
/
Humans
langue:
En
Texte intégral:
International Journal of Thyroidology
Année:
2019
Type:
Article